Margaret McJannett
A5000296685- Prostate Cancer Treatment and Research
- Radiopharmaceutical Chemistry and Applications
- Cancer Immunotherapy and Biomarkers
- Cancer, Lipids, and Metabolism
- Patient-Provider Communication in Healthcare
- Testicular diseases and treatments
- Childhood Cancer Survivors' Quality of Life
- Cancer Treatment and Pharmacology
- Palliative Care and End-of-Life Issues
- Cancer survivorship and care
- Prostate Cancer Diagnosis and Treatment
- Bladder and Urothelial Cancer Treatments
- Urologic and reproductive health conditions
- Renal cell carcinoma treatment
- Advances in Oncology and Radiotherapy
- Economic and Financial Impacts of Cancer
- Genetic factors in colorectal cancer
- Healthcare Systems and Technology
- Sexual Differentiation and Disorders
- Medical Imaging Techniques and Applications
- COVID-19 and healthcare impacts
- Multiple Myeloma Research and Treatments
- Cancer Research and Treatments
- Colorectal Cancer Screening and Detection
- Urinary and Genital Oncology Studies
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
2014-2025
Clinical Trials New Zealand
2021
Astellas Pharma (United Kingdom)
2021
Sanofi (France)
2021
Janssen (Belgium)
2021
Bayer (United States)
2021
Pfizer (United Kingdom)
2021
AstraZeneca (Poland)
2021
Astellas Pharma (China)
2021
The University of Sydney
2003-2017
Enzalutamide, an androgen-receptor inhibitor, has been associated with improved overall survival in men castration-resistant prostate cancer. It is not known whether adding enzalutamide to testosterone suppression, or without early docetaxel, will improve metastatic, hormone-sensitive cancer.In this open-label, randomized, phase 3 trial, we assigned patients receive suppression plus either open-label a standard nonsteroidal antiandrogen therapy (standard-care group). The primary end point...
Objective To assess the activity and safety of cabazitaxel chemotherapy vs that treatment with 177 Lu‐ PSMA ‐617, a novel radiolabelled small molecule binds high affinity to prostate‐specific membrane antigen ( ), in men metastatic castration‐resistant prostate cancer mCRPC ) who have received prior docetaxel treatment. Patients methods The TheraP trial ANZUP 1603) is an open‐label, randomized, stratified, two‐arm multicentre phase 2 comparing ‐617 therapy . Key eligibility criteria include...
5000 Background: We previously reported that in men with mCRPC progressing after docetaxel randomly assigned LuPSMA vs. cabazitaxel (Lancet 2021), those has significant improvements PSA response rate (66% 37%), RECIST (49% 24%), progression-free survival (HR 0.63), less G3-4 toxicities (33% 53%) and better patient-reported outcomes. now report the secondary endpoint of overall (OS) mature follow-up, for trial participants, also initially excluded because low PSMA-expression or discordant...
Decision making in advanced cancer is increasingly complex. We developed a decision aid (DA) for patients with colorectal who are considering first-line chemotherapy and reviewing treatment options, prognostic information, toxicities. examined its impact on patient understanding, decisions, decisional conflict, making, consultation satisfaction, anxiety, quality of life by using randomized trial design.In all, 207 were metastatic disease randomly assigned to receive standard medical oncology...
5500 Background: LuPSMA is a radiolabeled small molecule that delivers therapeutic β-radiation to PSMA-expressing tumors. Encouraging efficacy and safety has been shown in non-randomized studies of mCRPC. TheraP randomized phase II trial comparing vs cabazitaxel men with mCRPC progressing after docetaxel. Methods: Men mCRPC, imaging 68 Ga-PSMA-11 18 F-FDG PET/CT confirmed high PSMA-expression no sites FDG-positive/PSMA-negative disease, were randomly assigned (1:1) (6-8GBq q6weeks up 6...
We previously reported that enzalutamide improved overall survival when added to standard of care in metastatic, hormone-sensitive prostate cancer. Here, we report its effects on aspects health-related quality life (HRQL).HRQL was assessed with the European Organisation for Research and Treatment Cancer core quality-of-life questionnaire QLM-PR25 at weeks 0, 4, 12, then every 12 until progression. Scores from week 4 156 were analyzed repeated measures modeling calculate group means...
Plain Language SummaryWhat is this summary about?ENZAMET a large international clinical trial involving people with metastatic hormone sensitive prostate cancer (mHSPC). Prior to the trial, standard treatment included testosterone suppression and sometimes, chemotherapy. However, researchers thought enzalutamide, an anti-androgen (hormone) medicine, which helps block effects of testosterone, might be helpful if added suppression.What are key takeaways?ENZAMET showed that addition...
To determine the activity and safety of lutetium-177 (177 Lu)-prostate-specific membrane antigen (PSMA)-617 in men with metastatic castration-resistant prostate cancer (mCRPC) commencing enzalutamide, who are at high risk early progression, to identify potential prognostic predictive biomarkers from imaging, blood tissue.ENZA-p (ANZUP 1901) is an open-label, randomized, two-arm, multicentre, phase 2 trial. Participants randomly assigned (1:1) treatment enzalutamide 160 mg daily alone or plus...
10 Background: The TheraP trial showed that LuPSMA improved PSA≥50% response rate (PSA50-RR), PSA-PFS, and radiographic PFS (rPFS) compared with cabazitaxel in mCRPC progressing after docetaxel. Study inclusion required high PSMA uptake (SUVmax≥20) no lesions were FDG+ PSMA-. Here we report on PET FDG as potential predictive prognostic biomarkers. Methods: We prospectively analysed semi-automated quantitative parameters centrally- collected 68 Ga-PSMA-11 18 F-FDG 200 eligible men. SUVmean...
e-TC is an online intervention designed to address common psychosocial concerns of testicular cancer survivors. It aims reduce anxiety, depression and fear recurrence by providing evidence-based information psychological intervention. This paper details the development pilot testing e-TC. During testing, 25 men (with varying profiles) who had completed treatment for cancer, 6 months 5 years ago (which not recurred), used over a 10-week period provided quantitative qualitative feedback on...
A question prompt list (QPL) is a structured of questions designed to encourage patients acquire information during medical consultation. It has been shown be an effective, inexpensive means helping cancer ask in certain content areas when consulting oncologist. The objective this study was develop QPL for seeing surgeon initially, targeting issues identified by as important. Focus groups and interviews were convened with 22 patients. One focus group conducted allied health professionals....
International guidelines advocate for active surveillance as the preferred treatment strategy patients with stage 1 testicular cancer after orchidectomy although a personalized discussion is required.
485 Background: In patients (pts) with muscle invasive bladder (MIBC) suitable for curative definitive chemoradiotherapy (CRT), we hypothesise that the addition of pembrolizumab may be safe and improve efficacy. A pre-planned safety analysis was performed after first 10 planned 30 pts were enrolled completed treatment. Methods: Patients maximally resected non-metastatic MIBC ECOG 0-1, who desire preservation or are ineligible cystectomy treated 64Gy in 32 daily radiation fractions to whole...
428 Background: Rare variant non-clear cell renal cancer (nccRCC) have diverse biology and therapeutic response. Immune checkpoint immunotherapy (ICI) can benefit some people with nccRCC, but many experience progression. We sought to test cabozantinib (C) in nccRCC refractory to, or unsuitable for ICI. Methods: Eligible participants (pts) had advanced/metastatic good ECOG PS (<2) either prior treatment ICI were due a contraindicating autoimmune disorder. Pts urothelial collecting duct...
TPS177 Background: 177 Lu‐PSMA‐617 (LuPSMA) is a novel radionuclide with promising activity and tolerability in metastatic, castration-resistant prostate cancer (mCRPC). Pre-clinical studies have shown that androgen receptor blockade enzalutamide upregulates PSMA-receptor expression, increases treatment response to enzalutamide. We hypothesise concurrent administration of LuPSMA will be synergistic mCRPC. The aims ENZA-p are determine the safety men mCRPC at high-risk early progression on...
TPS5100 Background: There is impetus to identify biomarkers in TGCT help select those at high-risk of relapse following orchiectomy and target interventions prevent over-treatment. miR-371 has been shown reliably predict presence active malignancy with higher accuracy than currently available biomarkers. More clinical evidence required ascertain its utility as a marker microscopic disease guide treatment recommendations stage 1 other settings. Methods: CLIMATE ANZUP1906 (ACTRN12622000247774)...
TPS332 Background: Lutetium-177 [ 177 Lu]-PSMA-617 is a novel radiolabelled small molecule that binds with high affinity to prostate-specific membrane antigen (PSMA), which commonly overexpressed in prostate cancer. This treatment has demonstrated promising activity and tolerability men progressing after multiple lines of chemotherapy endocrine therapy. trial will determine the safety Lu-PSMA-617 compared cabazitaxel progressive metastatic castrate resistant Methods: TheraP an open-label,...